This retrospective cohort study aims to examine the influence of HER2 status (HER2-low vs. HER2-zero) on the pathological response to neoadjuvant chemotherapy in breast cancer patients and to assess the HER2 status regarding survival outcomes in early-stage breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.